stockrow
Friday 6 November 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
0.63
0.01
+1.61%
Follow LAB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 4 |
+8 more TTM periods Free account |
| 27.86% | 17.61% | 15.40% | (16.72%) | ||
| 22.65% | 14.34% | 12.83% | (12.69%) | ||
ROIC |
(54.18%) | (93.89%) | (56.34%) | (29.07%) | |
Return on Tangible Assets |
28.96% | 17.86% | 15.76% | (20.51%) | |
Average Days of Receivables |
56.12 | 67.94 | 176.19 | 57.45 | |
Free Cash Flow per Share |
(0.17) | (0.21) | (0.24) | (0.22) | |
Free Cash Flow |
(65.65) | (82.58) | (94.48) | (82.65) | |
Capital Expenditures |
(1.39) | (2.28) | (3.82) | (8.30) | |
| Other line items | |||||
Cash ROIC |
(6.45%) | (8.12%) | (9.29%) | (13.50%) | |
Accounts Receivable Turnover |
6.37 | 5.57 | 2.24 | 6.06 | |
Accounts Payable Turnover |
8.02 | 4.96 | 4.39 | 8.18 | |
Inventory Turnover |
1.88 | 2.03 | 1.43 | 2.10 | |
Average Days of Payables |
31.21 | 83.25 | 67.26 | 46.12 | |
Days of Inventory on Hand |
159.25 | 149.03 | 156.19 | 170.45 | |
Tax Rate |
(0.49) | (0.41) | (0.43) | (0.39) | |
Research and Development Expense of Revenue |
16.75% | 21.77% | 26.28% | 30.45% | |
Selling, General and Administrative Expense of Revenue |
91.41% | 102.75% | 114.36% | 128.75% | |
Share Based Compensation of Revenue |
26.46% | 32.02% | 34.12% | 34.70% | |
Interest Coverage |
— | — | — | (2,979.70) | |
Operating CF/Net income |
(0.48) | (0.95) | (1.16) | 0.99 | |
Depreciation/Fixed assets |
0.13 | 0.17 | 0.34 | 0.43 | |
Capex/Depreciation |
(0.83) | (0.88) | (0.66) | (1.00) | |
Revenue per Share |
0.21 | 0.22 | 0.22 | 0.22 | |
Operating CF per Share |
(0.16) | (0.21) | (0.23) | (0.19) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.02 | 0.03 | 0.04 | 0.10 |
Columns are period end dates · fundamentals updated 5 Nov 2026